Century Health, a pioneer in applying AI to real-world data to accelerate research and advance therapeutics, and Memory Treatment Centers, a national leader in neurocognitive disease care, announced a partnership to transform unstructured clinical data into research-grade real-world evidence. This enables rapid understanding of disease progression and how novel therapies for Alzheimer’s disease perform outside clinical trials.
Health Technology Insights: HAPPE Spine Reaches 1,000 Patients with the INTEGRATE-C Interbody Fusion System
The Century Health Abstraction and Retrieval Model (CHARM) will extract and standardize key variables, such as treatment response, cognitive assessments, genetic risk factors like Apolipoprotein E (APOE), and imaging findings like amyloid-related imaging abnormalities (ARIA). Century Health specializes in extracting clinical insights from unstructured clinical notes and imaging data, reducing the need for costly new data collection. These structured, de-identified data enable analysis of treatment effectiveness and safety across diverse patient populations, supporting hypothesis generation and post-market research at scale.
All analyses use de-identified data and adhere to strict HIPAA-compliant privacy safeguards. The resulting high-quality, compliant datasets can be used by clinicians, investigators, and pharmaceutical partners to assess treatment effectiveness, real-world safety, and value across populations. This evidence helps bridge real-world outcomes to research and access decisions, enabling continuous learning about safety, effectiveness, and patient impact across the treatment lifecycle.
Health Technology Insights: Peptisystems Gets Rubicon Funding to Boost Growth
“Memory Treatment Centers is dedicated to advancing care for Alzheimer’s disease and other forms of dementia,” said Dr. Bobby Mannel, neurologist and co-founder of Memory Treatment Centers. “By collaborating with Century Health, we can analyze how new treatments perform in real-world settings and learn how to optimize care for every patient we serve.”
Memory Treatment Centers has been at the forefront of Alzheimer’s treatment. The group was the first in the US to administer donanemab and lecanemab, FDA-approved therapies shown to slow early Alzheimer’s progression by targeting amyloid plaques. Memory Treatment Centers’ comprehensive approach to diagnosis and care has established it as one of the nation’s leading centers for early adoption and real-world monitoring of disease-modifying treatments.
“Practices serving the most affected populations often hold uniquely powerful data to inform clinical and translational research,” said Vish Srivastava, Co-Founder & CEO at Century Health. “By partnering with one of the largest and most advanced Alzheimer’s and dementia practices in the country, we can help translate everyday care data into insights that directly shape future treatments.”
Research into Alzheimer’s disease is critical, as it is a progressive disease with no cure. More than 7 million people in the US live with the disease presently, and that number is expected to double by 2060. With Florida among the states with the highest populations of Alzheimer’s patients in the country, the partnership highlights the importance of scalable, real-world research in community settings to advance understanding and improve outcomes.
Health Technology Insights: OnPoint Surgical Names Jeremy Laynor Chief Commercial Officer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
